FDA Expands Moderna’s RSV Vaccine Indications

The U.S. FDA has broadened the approved use of Moderna’s mRESVIA vaccine for respiratory syncytial virus (RSV) to include at-risk adults aged 18 and older. This regulatory action follows closely after the approval of Moderna’s new Covid-19 vaccine, enhancing protection options for vulnerable adult populations susceptible to RSV-associated respiratory illness.